Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

One of the most significant insights from the study is that roboticists must engage both technically and physically with ...

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...

With the popularity of AI coding tools rising among some software developers, their adoption has begun to touch every aspect ...

For decades, software developers have been slipping jokes into their work. One of the most enduring, clever, and geekily satisfying inside jokes has been hiding in plain sight: the recursive acronym.

After Balancer and Yearn suffered major exploits, new entrants like Axis are betting that transparency and off-chain ...

November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches([1]) . The global anticancer drug market now values ...

Oncolytics Biotech Inc. (NASDAQ: ONCY) has secured FDA alignment on its pivotal Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning the company to launch the ...

And other pharma news rounded up from around the Pharmalot campus, as told to you by the Pharmalittle newsletter ...

As language models (LMs) improve at tasks like image generation, trivia questions, and simple math, you might think that ...

As language models (LMs) improve at tasks like image generation, trivia questions, and simple math, you might think that ...